<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601705</url>
  </required_header>
  <id_info>
    <org_study_id>CASE2Y07</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE2Y07</secondary_id>
    <secondary_id>NCI-2010-01196</secondary_id>
    <nct_id>NCT00601705</nct_id>
  </id_info>
  <brief_title>Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach</brief_title>
  <official_title>A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and
      cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill
      tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the
      amount of normal tissue that needs to be removed. Giving chemotherapy and radiation therapy
      after surgery may kill any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying how well giving combination chemotherapy, surgery,
      and radiation therapy works in treating patients with locoregionally advanced cancer of the
      esophagus, gastroesophageal junction, or stomach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the feasibility and tolerability of induction chemotherapy comprising
           epirubicin hydrochloride, oxaliplatin, and fluorouracil (EOF), followed by surgical
           resection and postoperative concurrent chemoradiotherapy comprising fluorouracil and
           cisplatin in patients with locoregionally advanced adenocarcinoma of the esophagus,
           gastroesophageal junction, or gastric cardia.

      Secondary

        -  To determine the rate of complete and partial response to three courses of EOF induction
           chemotherapy.

        -  To compare the recurrence-free and overall survival of patients treated with this
           regimen vs historical controls at this institution.

        -  To compare patterns of failure in patients treated with this regimen vs historical
           controls at this institution.

      OUTLINE:

        -  Induction chemotherapy: Patients receive epirubicin hydrochloride IV over 3-15 minutes
           and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-21.
           Treatment repeats every 21 days for up to 3 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Surgery: Four weeks after completion of induction chemotherapy, patients with
           locoregionally confined disease (T0-4, N0-1, M0-1a) undergo transthoracic
           esophagogastrectomy or total gastrectomy with Roux-en-Y esophagojejunostomy, depending
           on the location and extent of the tumor at the time of surgery.

        -  Postoperative chemoradiotherapy: Beginning 6-10 weeks after surgery, patients undergo
           radiotherapy 5 days a week for approximately 6 weeks. Patients also receive fluorouracil
           IV continuously and cisplatin IV continuously over 96 hours in weeks 1 and 4 of
           radiotherapy.

      After completion of study treatment, patients are followed every 8-12 weeks for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2008</start_date>
  <completion_date type="Actual">January 23, 2015</completion_date>
  <primary_completion_date type="Actual">March 26, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate</measure>
    <time_frame>at 12 weeks from on study</time_frame>
    <description>Feasibility of induction chemoradiotherapy as measured by resectability in greater than 75% of participants. The number of participants that were resectable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>at 12 weeks from on study</time_frame>
    <description>Percent of participants with a clinical response:
Complete clinical response is defined as the complete disappearance of all clinical evidence of tumor.
Partial clinical response is defined as any improvement in the clinically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable clinical disease is defined as no change in the clinical TNM stage when compared to the pretreatment clinical stage.
Progressive clinical disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Response Rate</measure>
    <time_frame>after completion of study at 35 weeks</time_frame>
    <description>Percent of participants with a clinical response:
Complete pathologic response is defined as the complete disappearance of all viable tumor in the surgical specimen.
Partial pathologic response is defined as any improvement in the pathologically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment esophageal ultrasound-determined clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable pathologic disease is defined as no change in the pathologically determined TNM stage when compared to the pretreatment esophageal ultrasound.
Progressive pathologic disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at 3 years from on study</time_frame>
    <description>Percent of participants with a 3-year survival. A survival rate greater than 50% would suggest efficacy and justify further study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Control and Distant Metastatic Control</measure>
    <time_frame>at 3 years from on study</time_frame>
    <description>A distant metastatic control rate of greater than 55 % would suggest efficacy for this treatment protocol. A locoregional control rate of less than 75% would suggest inefficacy. Locoregional control (LRC) defined by recurrence at the primary site or in regional lymph nodes and distant metastatic control (DMC), defined by recurrence in a distant site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Adjuvant Chemoradiotherapy Feasibility</measure>
    <time_frame>Between 6 to 10 weeks postoperatively</time_frame>
    <description>Ability to complete postoperative chemoradiotherapy. A threshold level of 65% was set and if less than this percentage completed the phase, it would be deemed unacceptable. The anticipation was that 53-patients would be evaluable for this end point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <description>50 mg/m2 IV bolus</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>130 mg/m2 IV infusion over 2 hours</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).
Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible.</description>
    <arm_group_label>Epirubicin, Oxaliplatin and Fluorouracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologic diagnosis of adenocarcinoma of the esophagus,
             gastroesophageal junction or gastric cardia, based on biopsy material or adequate
             cytologic exam.

          -  Patients must be clinically staged according to the AJCC 2002 staging system and must
             have either T3-4, or N1 or M1a disease. Staging should include at least an upper
             endoscopy with endoscopic ultrasound and an FDG-PET/CT scan.

          -  Patients must have an ECOG performance status of 0-1.

          -  Patients must have adequate bone marrow function as evidenced by: Absolute neutrophil
             count &gt; 1,500/uL Platelet count &gt; 100,000/uL

          -  Patients must have adequate renal function as evidenced by serum creatinine &lt; 1.6
             mg/dL

          -  Patients must have adequate hepatic function as evidenced by:Serum total bilirubin &lt;
             1.5 mg/dL Alkaline phosphatase &lt; 3X the institutional ULN AST/ALT &lt; 3X the
             institutional ULN

          -  Patients must have adequate pulmonary function as evidenced by an FEV1 &gt; 50%
             predicted.

          -  Patients or their legal representatives must be able to read, understand, provide and
             sign informed consent to participate in the trial.

          -  Patients of childbearing potential agree to use an effective form of contraception
             during the study and for 90 days following the last dose of study medication (an
             effective form of contraception is an oral contraceptive or a double barrier method)

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Patients with any other diagnosis except for adenocarcinoma (squamous cell carcinoma,
             small cell carcinoma, mixed adenosquamous, lymphoma, sarcoma etc,) will be ineligible.

          -  Patients with any evidence of distant hematogenous or distant nodal disease (M1b) will
             be ineligible.

          -  No prior chemotherapy, radiation therapy or surgery for this malignancy will be
             allowed. Prior endoscopic debulking, laser therapy or dilatation will not exclude a
             patient.

          -  Patients with another active malignancy will not be eligible except for curatively
             treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or
             localized prostate cancer with a current PSA of &lt; 1.0 mg/dL on 2 successive
             evaluations at least 3 months apart, with the most recent evaluation within 4 weeks of
             entry

          -  Patients with an active infection will not be eligible.

          -  Patients with known hypersensitivity to any of the components of oxaliplatin,
             epirubicin, fluorouracil or cisplatin will not be eligible.

          -  Patients who are receiving any other concurrent investigational therapy, or who have
             received investigational therapy within 30 days of the first scheduled day of protocol
             treatment (investigational therapy is defined as treatment for which there is
             currently no regulatory authority approved indication) will not be eligible.

          -  Patients with a baseline peripheral neuropathy greater than or equal Grade 2 will not
             be eligible.

          -  Patients who are pregnant or lactating will not be eligible.

          -  Patients with any other medical condition, including mental illness or substance
             abuse, deemed by the Investigator to be likely to interfere with a patient's ability
             to sign informed consent, cooperate and participate in the study, or interfere with
             the interpretation of the results, will not be eligible.

          -  Patients with any history of an allogeneic transplant will not be eligible.

          -  Patients with known infection with HIV, Hepatitis B or C (active, previously treated
             or both) will not be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Adelstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>February 21, 2019</results_first_submitted>
  <results_first_submitted_qc>April 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
          <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
          <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="37" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate</title>
        <description>Feasibility of induction chemoradiotherapy as measured by resectability in greater than 75% of participants. The number of participants that were resectable.</description>
        <time_frame>at 12 weeks from on study</time_frame>
        <population>All subjects that went on study and received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
            <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate</title>
          <description>Feasibility of induction chemoradiotherapy as measured by resectability in greater than 75% of participants. The number of participants that were resectable.</description>
          <population>All subjects that went on study and received treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate</title>
        <description>Percent of participants with a clinical response:
Complete clinical response is defined as the complete disappearance of all clinical evidence of tumor.
Partial clinical response is defined as any improvement in the clinically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable clinical disease is defined as no change in the clinical TNM stage when compared to the pretreatment clinical stage.
Progressive clinical disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
        <time_frame>at 12 weeks from on study</time_frame>
        <population>Participants that complete induction therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin and Fluorouracil</title>
            <description>Epirubicin, Oxaliplatin and Fluorouracil (EOF) followed by Esophagogastrectomy and post-operative concurrent chemoradiotherapy with Fluorouracil and Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate</title>
          <description>Percent of participants with a clinical response:
Complete clinical response is defined as the complete disappearance of all clinical evidence of tumor.
Partial clinical response is defined as any improvement in the clinically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable clinical disease is defined as no change in the clinical TNM stage when compared to the pretreatment clinical stage.
Progressive clinical disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
          <population>Participants that complete induction therapy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathological Response Rate</title>
        <description>Percent of participants with a clinical response:
Complete pathologic response is defined as the complete disappearance of all viable tumor in the surgical specimen.
Partial pathologic response is defined as any improvement in the pathologically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment esophageal ultrasound-determined clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable pathologic disease is defined as no change in the pathologically determined TNM stage when compared to the pretreatment esophageal ultrasound.
Progressive pathologic disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
        <time_frame>after completion of study at 35 weeks</time_frame>
        <population>Participants that complete induction therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin and Fluorouracil</title>
            <description>Epirubicin, Oxaliplatin and Fluorouracil (EOF) followed by Esophagogastrectomy and post-operative concurrent chemoradiotherapy with Fluorouracil and Cisplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Response Rate</title>
          <description>Percent of participants with a clinical response:
Complete pathologic response is defined as the complete disappearance of all viable tumor in the surgical specimen.
Partial pathologic response is defined as any improvement in the pathologically determined T or N stage (without reciprocal deterioration in N or T) or a resolution of M1a disease, when compared to the pretreatment esophageal ultrasound-determined clinical stage. A partial response will not be defined based only on shrinkage of a measurable lesion unless there is improvement in the TNM stage.
Stable pathologic disease is defined as no change in the pathologically determined TNM stage when compared to the pretreatment esophageal ultrasound.
Progressive pathologic disease is defined as any increase in the T or N stage irrespective of any reciprocal improvement in N or T, or as the development of new areas of malignancy or metastases.</description>
          <population>Participants that complete induction therapy</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percent of participants with a 3-year survival. A survival rate greater than 50% would suggest efficacy and justify further study.</description>
        <time_frame>at 3 years from on study</time_frame>
        <population>All patients that went on study</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
            <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percent of participants with a 3-year survival. A survival rate greater than 50% would suggest efficacy and justify further study.</description>
          <population>All patients that went on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Locoregional Control and Distant Metastatic Control</title>
        <description>A distant metastatic control rate of greater than 55 % would suggest efficacy for this treatment protocol. A locoregional control rate of less than 75% would suggest inefficacy. Locoregional control (LRC) defined by recurrence at the primary site or in regional lymph nodes and distant metastatic control (DMC), defined by recurrence in a distant site.</description>
        <time_frame>at 3 years from on study</time_frame>
        <population>All participants that went on study</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
            <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Locoregional Control and Distant Metastatic Control</title>
          <description>A distant metastatic control rate of greater than 55 % would suggest efficacy for this treatment protocol. A locoregional control rate of less than 75% would suggest inefficacy. Locoregional control (LRC) defined by recurrence at the primary site or in regional lymph nodes and distant metastatic control (DMC), defined by recurrence in a distant site.</description>
          <population>All participants that went on study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Locoregional Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant Metastatic Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Adjuvant Chemoradiotherapy Feasibility</title>
        <description>Ability to complete postoperative chemoradiotherapy. A threshold level of 65% was set and if less than this percentage completed the phase, it would be deemed unacceptable. The anticipation was that 53-patients would be evaluable for this end point.</description>
        <time_frame>Between 6 to 10 weeks postoperatively</time_frame>
        <population>All patients that went on study</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, 5-fluorouracil, and Surgery</title>
            <description>Subjects received epirubicin (50-mg/m^2), oxaliplatin (130-mg/m^2), 5-fluorouracil (5FU; 200mg/m^2/d), and surgery, which took place 4 to 5 weeks after the completion of preoperative chemotherapy. Epirubicin and oxaliplatin were given on day 1, while 5FU was intravenously infused for 21-days. Surgery was conducted 4 to 5-weeks after chemotherapy. Six to ten-weeks after surgery chemoradiotherapy was initiated. With radiotherapy, patients received two cycles of cisplatin and 5FU during the first and fourth weeks after surgery; they were administered intravenously over 96-hours. Specifically, cisplatin and 5FU total dose was 80-mg/m^2 (20-mg/m^2/d) and 4000 mg/m^2 (1000-mg/m^2/d), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Adjuvant Chemoradiotherapy Feasibility</title>
          <description>Ability to complete postoperative chemoradiotherapy. A threshold level of 65% was set and if less than this percentage completed the phase, it would be deemed unacceptable. The anticipation was that 53-patients would be evaluable for this end point.</description>
          <population>All patients that went on study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for adverse events while on study, treatment and the 30 days following treatment discontinuation over a period of up to 1 year.</time_frame>
      <desc>Adverse events were reported separately for pre-operative therapy (60 participants) and post-operative therapy (48 participants).</desc>
      <group_list>
        <group group_id="E1">
          <title>Epirubicin, Oxaliplatin and Fluorouracil</title>
          <description>cisplatin: 20 mg/m2/day IV continuous infusion over 24 hours for 96 hours.
epirubicin hydrochloride: 50 mg/m2 IV bolus
fluorouracil: 200 mg/m2/day continuous infusion for all 9 weeks, beginning on day 1.
oxaliplatin: 130 mg/m2 IV infusion over 2 hours
adjuvant therapy: At 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given. Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
neoadjuvant therapy: Three weeks after discontinuing the fluorouracil patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for app</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Enteritis - inflammation of the small bowel</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fistula, GI - Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <description>Clostridium Difficile</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>fainting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Preoperative therapy</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Platelets &lt;50,000/l</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>wound infections</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chylothorax</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <description>Preoperative therapy</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <description>Postoperative therapy</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Adelstein</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216 444-9310</phone>
      <email>ADELSTD@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

